Related Experiment Video
Updated: May 26, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice
Vladislav Volarevic1, Marija Milovanovic, Biljana Ljujic
1Center for Molecular Medicine and Stem Cell Research, Faculty of Medicine, University of Kragujevac, Kragujevac, Serbia.
Unlabelled:
We used concanavalin A (Con A)-induced liver injury to study the role of galectin-3 (Gal-3) in the induction of inflammatory pathology and hepatocellular damage. We tested susceptibility to Con A-induced hepatitis in galectin-3-deficient (Gal-3(-/-)) mice and analyzed the effects of pretreatment with a selective inhibitor of Gal-3 (TD139) in wild-type (WT) C57BL/6 mice, as evaluated by a liver enzyme test, quantitative histology, mononuclear cell (MNC) infiltration, cytokine production, intracellular staining of immune cells, and percentage of apoptotic MNCs in the liver. Gal-3(-/-) mice were less sensitive to Con A-induced hepatitis and had a significantly lower number of activated lymphoid and dendritic cells (DCs) in the liver. The level of tumor necrosis factor alpha (TNFα), interferon gamma (IFNγ), and interleukin (IL)-17 and -4 in the sera and the number of TNFα-, IFNγ-, and IL-17- and -4-producing cluster of differentiation (CD)4(+) cells as well as IL-12-producing CD11c(+) DCs were lower, whereas the number of IL-10-producing CD4(+) T cells and F4/80(+) macrophages were significantly higher in livers of Gal-3(-/-) mice. Significantly higher percentages of late apoptotic Annexin V(+) propidium-idodide(+) liver-infiltrating MNCs and splenocytes were observed in Gal-3(-/-) mice, compared to WT mice. Pretreatment of WT C57BL/6 mice with TD139 led to the attenuation of liver injury and milder infiltration of IFNγ- and IL-17- and -4-producing CD4(+) T cells, as well as an increase in the total number of IL-10-producing CD4(+) T cells and F4/80(+) CD206(+) alternatively activated macrophages and prevented the apoptosis of liver-infiltrating MNCs.
Conclusions:
Gal-3 plays an important proinflammatory role in Con A-induced hepatitis by promoting the activation of T lymphocytes and natural killer T cells, maturation of DCs, secretion of proinflammatory cytokines, down-regulation of M2 macrophage polarization, and apoptosis of MNCs in the liver.
Insights
Galectin-3 (Gal-3) promotes liver inflammation and damage in concanavalin A (Con A)-induced hepatitis. Inhibiting Gal-3 reduces liver injury, inflammatory cell infiltration, and apoptosis, suggesting Gal-3 as a therapeutic target.
Area of Science:
- Immunology
- Hepatology
- Molecular Biology
Background:
- Concanavalin A (Con A)-induced hepatitis is a model for studying immune-mediated liver injury.
- Galectin-3 (Gal-3) is implicated in inflammatory processes, but its specific role in Con A-induced hepatitis is not fully understood.
Purpose of the Study:
- To investigate the role of Gal-3 in Con A-induced liver injury.
- To evaluate the therapeutic potential of Gal-3 inhibition in this model.
Main Methods:
- Comparison of Con A-induced hepatitis in galectin-3-deficient (Gal-3(-/-)) mice and wild-type (WT) mice.
- Treatment of WT mice with a selective Gal-3 inhibitor (TD139).
- Assessment of liver enzymes, histology, immune cell infiltration (mononuclear cells, lymphocytes, dendritic cells), cytokine production (TNFα, IFNγ, IL-17, IL-4, IL-10), and apoptosis.
Main Results:
- Gal-3(-/-) mice exhibited reduced sensitivity to Con A-induced hepatitis with lower immune cell activation and pro-inflammatory cytokine levels.
- TD139 treatment attenuated liver injury, reduced inflammatory cell infiltration, and modulated cytokine profiles in WT mice.
- Gal-3 deficiency and inhibition led to increased IL-10 production, alternative macrophage activation, and reduced apoptosis of liver-infiltrating cells.
Conclusions:
- Gal-3 plays a significant pro-inflammatory role in Con A-induced hepatitis.
- Gal-3 promotes T lymphocyte and NK T cell activation, dendritic cell maturation, pro-inflammatory cytokine secretion, M2 macrophage polarization suppression, and mononuclear cell apoptosis.
- Targeting Gal-3 with inhibitors like TD139 shows therapeutic promise for mitigating liver inflammation and injury.

